8-KAcquisitions & DispositionsMaterial AgreementsFinancial Events+2

QUEST DIAGNOSTICS INC 8-K Report, Material Agreement (Jun 6, 2007)

Filed June 6, 2007For Securities:DGX

Summary

Quest Diagnostics Incorporated (DGX) filed an 8-K on June 6, 2007, reporting on significant financing activities and the completion of a major acquisition. The company entered into new credit agreements totaling $2.35 billion, comprising a $1.6 billion term loan facility and a $750 million revolving credit facility, along with a $1 billion bridge loan facility. These new credit facilities were primarily used to finance the acquisition of AmeriPath Group Holdings, Inc. for approximately $2 billion, repay AmeriPath's existing debt, and refinance a prior bridge loan used for the HemoCue acquisition. The acquisition of AmeriPath, a significant player in the diagnostics industry, was completed on May 31, 2007. This strategic move positions Quest Diagnostics for enhanced market presence and operational synergies. The filing details the structure of the new credit facilities, including repayment schedules, interest rate mechanisms, and covenants, as well as the terms of the AmeriPath acquisition, including the treatment of outstanding stock options and the assumption of AmeriPath's debt. Investors should note the substantial increase in the company's debt load to fund this acquisition, alongside the potential benefits derived from integrating AmeriPath's operations.

Key Highlights

  • 1Quest Diagnostics secured new credit facilities totaling $2.35 billion ($1.6B term loan, $750M revolving credit) and a $1B bridge loan.
  • 2The company completed the acquisition of AmeriPath Group Holdings, Inc. for approximately $2 billion.
  • 3Proceeds from the new credit facilities were used to fund the AmeriPath acquisition, repay AmeriPath's debt, and refinance a prior bridge loan.
  • 4The existing $500 million revolving credit facility was replaced by a new, larger revolving credit facility maturing in May 2012.
  • 5The AmeriPath acquisition involved the assumption of approximately $780 million of AmeriPath's indebtedness.
  • 6Stock options from AmeriPath were either cashed out (vested) or converted into Quest Diagnostics stock options (unvested).
  • 7The company announced it received requisite consents for a tender offer and consent solicitation for AmeriPath's 10½% Senior Subordinated Notes due 2013.

Frequently Asked Questions

The primary purpose of the new credit agreements was to finance the acquisition of AmeriPath Group Holdings, Inc., which cost approximately $2 billion. The funds were also used to repay virtually all of AmeriPath's existing debt and to repay a $450 million senior unsecured bridge loan taken out in January 2007 for the acquisition of HemoCue.

The acquisition was financed through borrowings under the new credit agreements (a $1.6 billion term loan and $500 million under the bridge credit agreement) and from Quest Diagnostics' existing cash on hand. The total consideration was approximately $2 billion, including the assumption of about $780 million in AmeriPath's debt.

The company significantly increased its debt load through these new credit facilities to fund the acquisition. The new revolving credit facility replaces an older one, and the term loan requires phased principal repayments starting in September 2007. The bridge loan has a shorter maturity date of May 2008. These facilities include financial covenants that could impact future financial flexibility.

Quest Diagnostics used proceeds from the new credit facilities and its cash on hand to repay virtually all of AmeriPath's existing indebtedness, including the assumption of approximately $780 million of debt as part of the acquisition and the tender offer for AmeriPath's 10½% Senior Subordinated Notes due 2013.